Skip to main content
Top
Published in: Medical Oncology 12/2014

01-12-2014 | Original Paper

Association of FoxP3 rs3761548 polymorphism with susceptibility to colorectal cancer in the Chinese population

Authors: Lei Chen, Qiming Yu, Bixia Liu, Liming Zhu

Published in: Medical Oncology | Issue 12/2014

Login to get access

Abstract

The aim of the present study was to determine the association of the Forkhead box P3 (FoxP3) rs3761548 polymorphism with the risk of colorectal cancer (CRC). Polymorphism genotyping was detected with polymerase chain reaction-polyacrylamide gel electrophoresis (PCR-PAGE), and data revealed that the AA, AC, and the combined A variant genotype (AA+AC) conferred a significantly greater risk of CRC [OR (95 % CI) = 2.806 (1.726–4.563), 1.54 (1.121–2.11), and 1.797 (1.344–2.404), respectively]. Moreover, the A allele of rs3761548 was observed to be associated with higher susceptibility of CRC [OR (95 % CI) = 1.792 (1.424–2.254)]. Unfortunately, no significant association was observed between the two subgroups after stratification by clinical characteristics including age; gender; tumor size, growth pattern, or differentiation; lymph node metastasis; and TNM pathological stage. Thus, we concluded that the FoxP3 gene polymorphism contributes to CRC susceptibility in a Chinese population.
Literature
1.
go back to reference Mitry E, Rachet B, Quinn MJ, Cooper N, Coleman MP. Survival from cancer of the rectum in England and Wales up to 2001. Br J Cancer. 2008;99(1):S30–2.PubMedCentralPubMedCrossRef Mitry E, Rachet B, Quinn MJ, Cooper N, Coleman MP. Survival from cancer of the rectum in England and Wales up to 2001. Br J Cancer. 2008;99(1):S30–2.PubMedCentralPubMedCrossRef
2.
go back to reference Galon J, Fridman WH, Pages F. The adaptive immunologic microenvironment in colorectal cancer: a novel perspective. Cancer Res. 2007;67:1883–6.PubMedCrossRef Galon J, Fridman WH, Pages F. The adaptive immunologic microenvironment in colorectal cancer: a novel perspective. Cancer Res. 2007;67:1883–6.PubMedCrossRef
3.
go back to reference Sakaguchi S. Naturally arising Foxp3-expressing CD25+ CD4+ regulatory T cells in immunological tolerance to self and non-self. Nat Immunol. 2005;6:345–52.PubMedCrossRef Sakaguchi S. Naturally arising Foxp3-expressing CD25+ CD4+ regulatory T cells in immunological tolerance to self and non-self. Nat Immunol. 2005;6:345–52.PubMedCrossRef
5.
go back to reference Kim M, Grimmig T, Grimm M, Lazariotou M, Meier E, Rosenwald A, et al. Expression of foxp3 in colorectal cancer but not in treg cells correlates with disease progression in patients with colorectal cancer. PLoS ONE. 2013;8:e53630.PubMedCentralPubMedCrossRef Kim M, Grimmig T, Grimm M, Lazariotou M, Meier E, Rosenwald A, et al. Expression of foxp3 in colorectal cancer but not in treg cells correlates with disease progression in patients with colorectal cancer. PLoS ONE. 2013;8:e53630.PubMedCentralPubMedCrossRef
6.
go back to reference Salama P, Phillips M, Grieu F, Morris M, Zeps N, Joseph D, et al. Tumor-infiltrating FOXP3+ T regulatory cells show strong prognostic significance in colorectal cancer. J Clin Oncol. 2009;27:186–92.PubMedCrossRef Salama P, Phillips M, Grieu F, Morris M, Zeps N, Joseph D, et al. Tumor-infiltrating FOXP3+ T regulatory cells show strong prognostic significance in colorectal cancer. J Clin Oncol. 2009;27:186–92.PubMedCrossRef
7.
go back to reference Clarke SL, Betts GJ, Plant A, Wright KL, El-Shanawany TM, Harrop R, et al. CD4+ CD25+ FOXP3+ regulatory T cells suppress anti-tumor immune responses in patients with colorectal cancer. PLoS ONE. 2006;1:e129.PubMedCentralPubMedCrossRef Clarke SL, Betts GJ, Plant A, Wright KL, El-Shanawany TM, Harrop R, et al. CD4+ CD25+ FOXP3+ regulatory T cells suppress anti-tumor immune responses in patients with colorectal cancer. PLoS ONE. 2006;1:e129.PubMedCentralPubMedCrossRef
8.
go back to reference Somasundaram R, Jacob L, Swoboda R, Caputo L, Song H, Basak S, et al. Inhibition of cytolytic T lymphocyte proliferation by autologous CD4+/CD25+ regulatory T cells in a colorectal carcinoma patient is mediated by transforming growth factor-β. Cancer Res. 2002;62:5267–72.PubMed Somasundaram R, Jacob L, Swoboda R, Caputo L, Song H, Basak S, et al. Inhibition of cytolytic T lymphocyte proliferation by autologous CD4+/CD25+ regulatory T cells in a colorectal carcinoma patient is mediated by transforming growth factor-β. Cancer Res. 2002;62:5267–72.PubMed
9.
go back to reference Bonertz A, Weitz J, Pietsch DH, Rahbari NN, Schlude C, Ge Y, et al. Antigen-specific Tregs control T cell responses against a limited repertoire of tumor antigens in patients with colorectal carcinoma. J Clin Investig. 2009;119:3311–21.PubMedCentralPubMed Bonertz A, Weitz J, Pietsch DH, Rahbari NN, Schlude C, Ge Y, et al. Antigen-specific Tregs control T cell responses against a limited repertoire of tumor antigens in patients with colorectal carcinoma. J Clin Investig. 2009;119:3311–21.PubMedCentralPubMed
11.
go back to reference Fontenot JD, Rasmussen JP, Williams LM, Dooley JL, Farr AG, Rudensky AY. Regulatory T cell lineage specification by the forkhead transcription factor foxp3. Immunity. 2005;22:329–41.PubMedCrossRef Fontenot JD, Rasmussen JP, Williams LM, Dooley JL, Farr AG, Rudensky AY. Regulatory T cell lineage specification by the forkhead transcription factor foxp3. Immunity. 2005;22:329–41.PubMedCrossRef
12.
go back to reference Zhang L, Zhang Y, Desrosiers M, Wang C, Zhao Y, Han D. Genetic association study of FOXP3 polymorphisms in allergic rhinitis in a Chinese population. Hum Immunol. 2009;70(11):930–4.PubMedCrossRef Zhang L, Zhang Y, Desrosiers M, Wang C, Zhao Y, Han D. Genetic association study of FOXP3 polymorphisms in allergic rhinitis in a Chinese population. Hum Immunol. 2009;70(11):930–4.PubMedCrossRef
13.
go back to reference Bossowski A, Borysewicz-Sańczyk H, Wawrusiewicz-Kurylonek N, Zasim A, Szalecki M, Wikiera B, et al. Analysis of chosen polymorphisms in FoxP3 gene in children and adolescents with autoimmune thyroid diseases. Autoimmunity. 2014;47(6):395–400.PubMedCrossRef Bossowski A, Borysewicz-Sańczyk H, Wawrusiewicz-Kurylonek N, Zasim A, Szalecki M, Wikiera B, et al. Analysis of chosen polymorphisms in FoxP3 gene in children and adolescents with autoimmune thyroid diseases. Autoimmunity. 2014;47(6):395–400.PubMedCrossRef
14.
go back to reference Gao L, Li K, Li F, Li H, Liu L, Wang L, et al. Polymorphisms in the FOXP3 gene in Han Chinese psoriasis patients. J Dermatol Sci. 2010;57(1):51–6.PubMedCrossRef Gao L, Li K, Li F, Li H, Liu L, Wang L, et al. Polymorphisms in the FOXP3 gene in Han Chinese psoriasis patients. J Dermatol Sci. 2010;57(1):51–6.PubMedCrossRef
15.
go back to reference Jahan P, Ramachander VR, Maruthi G, Nalini S, Latha KP, Murthy TS. Foxp3 promoter polymorphism (rs3761548) in breast cancer progression: a study from India. Tumour Biol. 2014;35(4):3785–91.PubMedCrossRef Jahan P, Ramachander VR, Maruthi G, Nalini S, Latha KP, Murthy TS. Foxp3 promoter polymorphism (rs3761548) in breast cancer progression: a study from India. Tumour Biol. 2014;35(4):3785–91.PubMedCrossRef
16.
go back to reference Lopes LF, Guembarovski RL, Guembarovski AL, Kishima MO, Campos CZ, Oda JM, et al. FOXP3 transcription Factor: a candidate marker for susceptibility and prognosis in triple negative breast cancer. Biomed Res Int. 2014;2014:341654.PubMed Lopes LF, Guembarovski RL, Guembarovski AL, Kishima MO, Campos CZ, Oda JM, et al. FOXP3 transcription Factor: a candidate marker for susceptibility and prognosis in triple negative breast cancer. Biomed Res Int. 2014;2014:341654.PubMed
17.
go back to reference Chen Y, Zhang H, Liao W, Zhou J, He G, Xie X, et al. FOXP3 gene polymorphism is associated with hepatitis B-related hepatocellular carcinoma in China. J Exp Clin Cancer Res. 2013;32:39.PubMedCentralPubMedCrossRef Chen Y, Zhang H, Liao W, Zhou J, He G, Xie X, et al. FOXP3 gene polymorphism is associated with hepatitis B-related hepatocellular carcinoma in China. J Exp Clin Cancer Res. 2013;32:39.PubMedCentralPubMedCrossRef
18.
go back to reference Littman DR, Rudensky A. Th17 and regulatory T Cells in mediating and restraining inflammation. Cell. 2010;140:845–58.PubMedCrossRef Littman DR, Rudensky A. Th17 and regulatory T Cells in mediating and restraining inflammation. Cell. 2010;140:845–58.PubMedCrossRef
20.
go back to reference Liu Z, Huang Q, Liu G, Dang L, Chu D, Tao K, et al. Presence of FOXP3(+)Treg cells is correlated with colorectal cancer progression. Int J Clin Exp Med. 2014;7(7):1781–5.PubMedCentralPubMed Liu Z, Huang Q, Liu G, Dang L, Chu D, Tao K, et al. Presence of FOXP3(+)Treg cells is correlated with colorectal cancer progression. Int J Clin Exp Med. 2014;7(7):1781–5.PubMedCentralPubMed
21.
go back to reference Ling A, Edin S, Wikberg ML, Öberg Å, Palmqvist R. The intratumoural subsite and relation of CD8(+) and FOXP3(+) T lymphocytes in colorectal cancer provide important prognostic clues. Br J Cancer. 2014;110(10):2551–9.PubMedCentralPubMedCrossRef Ling A, Edin S, Wikberg ML, Öberg Å, Palmqvist R. The intratumoural subsite and relation of CD8(+) and FOXP3(+) T lymphocytes in colorectal cancer provide important prognostic clues. Br J Cancer. 2014;110(10):2551–9.PubMedCentralPubMedCrossRef
22.
go back to reference Aiello M, Vella N, Cannavo C, Scalisi A, Spandidos DA, Toffoli G, et al. Role of genetic polymorphisms and mutations in colorectal cancer therapy. Mol Med Rep. 2011;4(2):203–8.PubMed Aiello M, Vella N, Cannavo C, Scalisi A, Spandidos DA, Toffoli G, et al. Role of genetic polymorphisms and mutations in colorectal cancer therapy. Mol Med Rep. 2011;4(2):203–8.PubMed
23.
go back to reference Winder T, Lenz HJ. Molecular predictive and prognostic markers in colon cancer. Cancer Treat Rev. 2010;36(7):550–6.PubMedCrossRef Winder T, Lenz HJ. Molecular predictive and prognostic markers in colon cancer. Cancer Treat Rev. 2010;36(7):550–6.PubMedCrossRef
Metadata
Title
Association of FoxP3 rs3761548 polymorphism with susceptibility to colorectal cancer in the Chinese population
Authors
Lei Chen
Qiming Yu
Bixia Liu
Liming Zhu
Publication date
01-12-2014
Publisher
Springer US
Published in
Medical Oncology / Issue 12/2014
Print ISSN: 1357-0560
Electronic ISSN: 1559-131X
DOI
https://doi.org/10.1007/s12032-014-0374-0

Other articles of this Issue 12/2014

Medical Oncology 12/2014 Go to the issue